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ABSTRACT
Proguanylin and prouroguanylin are the inactive precursors of guanylin and uroguanylin, natriuretic
peptides involved in the regulation of sodium balance. Urinary uroguanylin levels have been found
previously to be elevated in patients with HF (heart failure). The aim of the present study was to
investigate whether plasma proguanylin and prouroguanylin levels are increased in patients with HF
and to evaluate their relationship with cardiac and renal function. In this prospective observational
study, we recruited 243 patients with HF (151 men) and 72 healthy controls. In patients with HF,
plasma levels of proguanylin [median, 7.2 (range, 0.9–79.0) μg/l] and prouroguanylin [8.3 (1.7–
53.0 μg/l)] were both signiﬁcantly (P<0.0005) higher compared with levels in healthy controls
[5.5 (0.4–22.3 μg/l) for proguanylin and 6.3 (2.5–16.9) μg/l for prouroguanylin]. In patients with HF,
increased age, a history of hypertension, diabetes and atrial ﬁbrillation, use of diuretics, a higher
NYHA (New York Heart Association) class and a lower eGFR (estimated glomerular ﬁltration
rate) were signiﬁcant univariate predictors of proguanylin and prouroguanylin levels. In multivariate
analysis, a history of hypertension and low eGFR both had strong independent associations with
proguanylin and prouroguanylin levels. Proguanylin and prouroguanylin varied signiﬁcantly between
NYHAclasswithatrendofincreasingplasmaconcentrationswithworseningseverityofsymptoms.
In conclusion, plasma proguanylin and prouroguanylin are elevated in patients with HF. Elevated
plasma proguanylin and prouroguanylin levels are associated with hypertension, renal impairment
and increasing severity of HF. This novel endocrine system may contribute to the pathophysiology
of HF.
INTRODUCTION
HF (heart failure) is associated with progressive
impairment of sodium and water homoeostasis [1].
Guanylin [2] and uroguanylin [3] are 15- and 16-amino-
acid peptides with natriuretic activity involved in the
regulation of sodium balance in response to oral salt
intake [4]. Both are synthesized as inactive precursors,
proguanylin and prouroguanylin, which undergo post-
secretory processing by proteolytic cleavage to produce
their respective active moieties [5,6].
Guanylin and uroguanylin produce their natriuretic
effect by binding and activating cell-surface GC-C
(guanylate cyclase C) receptors located on gut mucosal
and renal tubular epithelial cells initiating a cGMP-
mediated second messenger cascade [7]. Guanylin
and uroguanylin have also been shown to induce
natriuresis in knockout mice lacking the GC-C receptor,
demonstrating a GC-C-independent pathway [8].
A previous study demonstrated a 70-fold increase
in uroguanylin-like bioactivity in the urine of patients
with HF compared with healthy controls, suggesting an
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important role of uroguanylin in the adaptive response
to HF [9]. However, this evidence was derived from
bioassays, which lack the speciﬁcity of immunoassays
and, thus, it was unclear whether urinary uroguanylin
concentration was elevated. Forte [10] has suggested that
uroguanylin may help regulate sodium balance via an
intestinal–renal natriuretic axis, as it is observed that oral
salt intake produces a more rapid natriuresis than an
equivalent intravenous sodium load in healthy subjects
[11].
We hypothesized that plasma proguanylin and
prouroguanylin are elevated in HF as part of the counter-
regulatory response to salt and water retention. Thus we
measured the plasma concentrations of these peptides in





referral cardiology centre in the present study. The
present study abided by the Declaration of Helsinki
and was approved by the local ethics committee.
Written informed consent was obtained from all of the
patients.
HF was diagnosed in patients fulﬁlling the following
two diagnostic criteria: (i) a history of worsening or new-
onset shortness of breath, and (ii) compatible clinical
signs of pulmonary rales, or elevated jugular venous
pressure or peripheral oedema. Patients could already
have a diagnosis of chronic HF or be a ﬁrst-presentation
of acute HF. Exclusion criteria were known malignancy
or surgery in the previous month. Renal function was
assessed using plasma creatinine and eGFR (estimated
glomerular ﬁltration rate), calculated from the simpliﬁed
formula derived from the MDRD (Modiﬁcation of Diet
and Renal Disease) study, validated in patients with HF
[12].
Plasma samples
Blood samples were drawn on presentation with HF
for determination of plasma levels of proguanylin and
prouroguanylin. After 15 min of bed rest, 20 ml of blood
was collected into tubes containing EDTA and aprotinin.
Allplasmawasstoredat−70◦Cuntilassayedinablinded
fashion in a single batch.
Echocardiography
Transthoracic echocardiography was performed in
patients with a Sonos 5500 instrument (Philips Medical
Systems). A 16-segment LVWMI [LV (left ventricular)
wall motion index] based on the American Society of
Echocardiography mode was derived by scoring each
left ventricle segment (1=normal; 2=hypokinesis; and
3=akinesis) and dividing the total by the number
of segments scored. LVEF (LV ejection fraction) was
calculated with the biplane method of discs formula.
Impaired LV systolic function was deﬁned as an LVEF
40% or an LVWMI 1.8.
Proguanylin and prouroguanylin assays
These assays were performed using antibodies and
standards from Biovendor. Polyclonal antibodies to
proguanylinorprouroguanylinwerecoatedontoELISA
plates. Plasma samples (20 μl for proguanylin and 50 μl
for prouroguanylin) were pipetted into the ELISA
plate wells together with appropriate standards up to
10 or 20 ng/ml respectively. After incubation for 1 h
at room temperature (25◦C), the plates were washed
and then the conjugated secondary polyclonal antibody
was pipetted into the wells for incubation for another
1 h. The prouroguanylin antibody was a biotinylated
antibody,andthesubsequentdetectionstepusedmethyl-
acridinium ester-labelled streptavidin on an MLX plate
luminometer (Dynex Technologies). The proguanylin
antibody was conjugated to horseradish peroxidase,
and subsequent detection used a colorimetric substrate
(3,3 ,5,5 -tetramethylbenzidine) measured on a Dynex
microplate reader with absorbance at 450 nm. The lower
limits of detection for proguanylin and prouroguanylin
were 0.45 and 0.65 ng/ml respectively. The recoveries of
proguanylinandprouroguanylinat5 ng/mlwere93.6and
101.8% respectively. Inter-assay coefﬁcients of variation
were 7.9% (at 13 ng/ml proguanylin; n=8) and 3.5%




Statistical analyses were performed on SPSS version 16.
Between-groupdifferences(healthyvolunteerscompared
with patients with HF) in plasma proguanylin and
prouroguanylin concentrations and in demographics
and clinical variables were compared using the
Mann–Whitney U test. Associations between plasma
proguanylin and prouroguanylin levels and clinical
variablesweredeterminedbySpearmancorrelations.The
association between NYHA (New York Heart Associ-
ation) class and plasma proguanylin and prouroguanylin
concentrations was assessed using one-way ANOVA
of log-transformed values with post-hoc correction for
multiple comparisons conducted using the Bonferroni
correction.Theabilityofdemographicfactorsandclinical
variables to inﬂuence proguanylin and prouroguanylin
levels was assessed using the General Linear Model with
log-transformed plasma proguanylin or prouroguanylin
concentrationsasthedependentvariable.Factorssigniﬁc-
ant in univariate analysis were entered as covariates into a
multivariate model to identify independent predictors of
plasma proguanylin and prouroguanylin concentrations.
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Table 1 Comparison between healthy controls and patients with HF
Values are medians (range) or numbers (percentage). P values were determined using a Mann–Whitney U test. ACEI, angiotensin-converting
enzyme inhibitor; CaAntagonist, calcium channel antagonist; LVIDD, LV internal diastolic dimension; MI, myocardial infarction.
Characteristic Controls (n=72) HF patients (n=243) P value
Age (years) 65.1 (50 to 80) 70 (20–95) 0.014
Male gender (n) 43 (59.7%) 151 (62.1%)
Proguanylin (μg/l) 5.5 (0.4–22.3) 7.2 (0.9–79.0) <0.0005
Prouroguanylin (μg/l) 6.3 (2.5–16.9) 8.3 (1.7–53.0) <0.0005
eGFR (ml · min−1 · 1.73 m−2 surface area) 71.8 (45.5–103.8) 50.6 (8.8–141.9) <0.0005
LVEF (%) 62.0 (51–77) 31.6 (15–45) <0.0005
LVIDD (mm) 45.0 (30–56) 63.0 (40–95) <0.0005
Past medical history (n)
Hypertension None 109 (44.9)
MI None 92 (37.9)
Diabetes None 43 (17.7)
Medication (n)
Diuretic None 192 (79.0)
β-Blocker None 97 (39.9)
ACEI None 163 (67.1)
CaAntagonist None 28 (11.5)
Non-normally distributed variables are expressed as
medians (range). A two-tailed P value of less than 0.05
was deemed to be statistically signiﬁcant.
RESULTS
DemographicfeaturesoftheHFandcontrolpopulations
are shown in Table 1. In the 72 healthy volunteers, there
were no signiﬁcant differences between plasma levels of
proguanylin and prouroguanylin in males [5.7 (0.4–13.0)
μg/l and 6.1 (2.5–16.9) μg/l) respectively] and females
[5.7 (3.3–22.3) μg/l and 7.2 (3.5–12.6) μg/l respectively].
Plasma proguanylin levels were signiﬁcantly (P<0.0005)
greater in patients with HF compared with healthy
controls as were prouroguanylin levels (Table 1 and
Figure 1).
Univariate analyses in patients with HF
Proguanylin and prouroguanylin levels had signiﬁcant
univariate associations in those patients with a previous
history of hypertension, diabetes, atrial ﬁbrillation and
a prescription of diuretics (Table 2). Plasma pro-
guanylin and prouroguanylin levels were signiﬁcantly
inversely correlated with eGFR in both healthy controls
(r=−0.329,P=0.021andr=−0.370,P=0.009respect-
ively) and patients with HF (r=−0.430, P<0.0005, and
r=−0.455, P<0.0005 respectively) (Figure 2). Plasma
proguanylin was signiﬁcantly correlated with increasing
age in healthy controls (r=0.349, P=0.003), but not
prouroguanylin(r=0.160,P=0.178),whereasbothwere
signiﬁcantly correlated in patients with HF (r=0.380,
Figure 1 Comparison of plasma proguanylin and prouro-
guanylin levels in healthy controls (n=72) with patients
with HF (n=243)
Plasma proguanylin and prouroguanylin were both signiﬁcantly elevated
(P <0.0005) in HF compared with healthy controls, as determined using the
Mann–Whitney U test.
P<0.0005, and r=0.323, P<0.0005 respectively).
Plasma levels of proguanylin and prouroguanylin were
strongly positively correlated with each other in both
healthy controls (r=0.574, P<0.0005) and patients with
HF (r=0.771, P<0.0005).
There were no strong associations between pro-
guanylin and prouroguanylin levels and echocardio-
graphic parameters of LV structure and function
(Table 2).
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Table 2 Univariate analysis of proguanylin and prouroguanylin in patients with HF
Values are medians (range). ACEI, angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction; CaAntagonist, calcium channel antagonist; LVIDD, LV internal diastolic dimension.
Analysis Proguanylin (μg/l) P value Prouroguanylin (μg/l) P value
Males compared with females 7.1 (0.94 – 79.0) compared with 7.3 (2.5–20.7) 0.500 7.8 (1.7–53.0) compared with 9.9 (2.9–43.9) 0.118
Previous medical history
AMI compared with none 7.2 (0.9–79.0) compared with 7.9 (1.8–30.7) 0.890 8.3 (1.9–53.0) compared with 9.2 (1.7–43.1) 0.941
Hypertension compared with none 8.6 (2.1–38.0) compared with 6.3 (0.9–79.0) 0.001 10.9 (1.7–43.9) compared with 6.9 (1.9–53.0) <0.0005
Diabetes compared with none 9.9 (2.5–24.5) compared with 7.0 (0.9–79.0) 0.004 11.2 (1.7–43.9) compared with 8.1 (1.9–53.0) 0.012
Atrial ﬁbrillation compared with none 10.3 (2.5–30.7) compared with 6.7 (0.9–79.0) 0.001 11.8 (3.9–43.8) compared with 8.1 (1.7–53.0) 0.002
Drug history
Diuretic compared with none 8.2 (0.9–79.0) compared with 5.2 (3.0–18.5) <0.0005 9.6 (1.7–53.0) compared with 6.5 (2.8–26.6) 0.003
β-Blocker compared with none 7.1 (0.9–38.0) compared with 7.6 (1.8–79.0) 0.218 7.1 (1.9–43.9) compared with 9.26 (1.7–53.0) 0.217
ACEI compared with none 7.8 (1.8–79.0) compared with 6.8 (0.9–35.3) 0.100 8.6 (1.7–53.0) compared with 6.9 (1.9–41.5) 0.168
CaAntagonist compared with none 5.4 (0.9–20.4) compared with 6.3 (1.8–79.0) 0.958 6.6 (1.9–41.5) compared with 7.6 (1.7–53.0) 0.669
Spearman correlation
Age 0.380 <0.0005 0.323 <0.0005
eGFR −0.430 <0.0005 −0.455 <0.0005
Creatinine 0.514 <0.0005 0.455 <0.0005
NYHA class 0.354 <0.0005 0.242 <0.0005
LVIDD −0.066 0.525 −0.095 0.363
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Figure 2 Relationship between eGFR and plasma pro-
guanylin (a) and prouroguanylin (b) in patients with HF
Spearman correlations: r =−0.430, P <0.0005 for proguanylin and eGFR, and
r =−0.455, P <0.0005 for prouroguanylin and eGFR.
HF: variation with severity
Plasma proguanylin and prouroguanylin both had a
generaltrendofincreasingconcentrationswithincreasing
NYHA class, with signiﬁcant variation between NYHA
classes (P<0.0005 for proguanylin and prouroguanylin;
Figure 3). In post-hoc analyses, plasma proguanylin
levels in patients with NYHA class III [8.43 (2.51–
79.0) μg/l] and class IV [8.83 (3.42–38.0) μg/l] were
signiﬁcantly (P<0.0005) greater than in healthy controls
[5.69 (0.42–22.3) μg/l] and those in NYHA class I [4.81
(0.95–14.6)μg/l].Similarly,plasmaprouroguanylinlevels
were signiﬁcantly greater in those in NYHA classes III
(P<0.0005) and IV (P=0.001) compared with healthy
controls [10.7 (1.7–3.0) μg/l and 10.2 (3.03–43.9) μg/l
compared with 6.32 (2.53–21.7) μg/l] and compared with
those in NYHA class I [6.46 (1.84–26.6) μg/l, P=0.002
and P=0.014 respectively].
Figure 3 Comparison of plasma proguanylin and prouro-
guanylin levels between healthy controls and patients in
different NYHA classes
Both proguanylin and prouroguanylin had a general trend of increasing levels
with increasing NHYA class, with signiﬁcant inter-group variation (P <0.0005)
using one-way ANOVA.
Predictors of proguanylin and
prouroguanylin in patients with HF
In univariate general linear model analysis, proguanylin
and prouroguanylin levels varied signiﬁcantly with
increasing age, a history of hypertension, diabetes, atrial
ﬁbrillation and diuretic use, NYHA class and eGFR
(Tables 3 and 4). In multivariate general linear model
analysis, the only independent predictors of proguanylin
and prouroguanylin levels were a history of hyper-
tension and lower eGFR (Tables 3 and 4).
DISCUSSION
The results of the present study demonstrate that plasma
proguanylin and prouroguanylin levels are elevated
in patients with HF. We have shown further that
plasma proguanylin and prouroguanylin levels were
independently associated with impaired renal function
and hypertension, with a trend of increasing plasma
proguanylin and prouroguanylin levels with increasing
severity of HF as measured by the NYHA class.
These results complement those of Carrithers et al.
[9],whofoundevidenceofincreasedurinaryuroguanylin
bioactivity in patients with HF. Increased plasma
proguanylin and prouroguanylin levels in HF are
most likely as a result of impaired renal clearance
leading to accumulation. Acute renal impairment
has been demonstrated to reduce the clearance of
circulating prouroguanylin, thus increasing its plasma
levels[13].Decreasedglomerularﬁltrationofplasmapro-
uroguanylin would result in reduced delivery of the
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Table 3 Predictors of plasma proguanylin level in patients with HF
Plasma proguanylin levels were log-transformed. ACEI, angiotensin-converting enzyme inhibitor; B, linear regression coefﬁcient; CaAntagonist, calcium channel antagonist;
CI, conﬁdence interval; LVIDD, LV internal diastolic dimension; MI, myocardial infarction.
Univariate Multivariate
Predictor B 95% CI P value B 95% CI P value
Age 0.01 0 to 0.01 <0.00005 0 −0.01 to 0 0.511
Gender 0.01 −0.06 to 0.08 0.750
Past medical history
MI 0 −0.08 to 0.07 0.930
Hypertension −0.11 −0.18 to −0.05 0.001 −0.31 −0.61 to −0.01 0.045
Diabetes −0.12 −0.20 to −0.03 0.010 −0.04 −0.23 to 0.14 0.637
Atrial ﬁbrillation −0.12 −0.21 to −0.04 0.003 −0.07 −0.26 to 0.12 0.481
Medication history
Diuretic −0.17 −0.25 to −0.09 <0.00005 −0.05 −0.65 to 0.74 0.897
β-Blocker 0.05 −0.16 to 0.12 0.131
ACEI −0.06 −0.14 to 0.01 0.078
CaAntagonist 0.02 −0.09 to 0.13 0.737
LVIDD 0 −0.01 to 0 0.659
NYHA 0.09 0.06 to 0.12 <0.00005 0.05 −0.01 to 0.11 0.083
eGFR −0.01 −0.01 to 0 <0.00005 0 −0.01 to 0 <0.00005
Table 4 Predictors of plasma prouroguanylin level in patients with HF
Plasma prouroguanylin levels were log-transformed. ACEI, angiotensin-converting enzyme inhibitor; B, linear regression coefﬁcient; CaAntagonist, calcium channel
antagonist; CI, conﬁdence interval; LVIDD, LV internal diastolic dimension; MI, myocardial infarction.
Univariate Multivariate
Predictor B 95% CI P value B 95% CI
Age 0.01 0 to 0.01 <0.00005 0 −0.01 to 0 0.630
Gender 0.06 −0.02 to 0.13 0.142
Past medical history
MI −0.01 −0.07 to 0.09 0.854
Hypertension −0.14 −0.21 to −0.07 <0.00005 −0.39 −0.72 to −0.06 0.021
Diabetes −0.11 −0.20 to −0.02 0.021 −0.01 −0.20 to 0.19 0.959
Atrial ﬁbrillation −0.14 −0.23 to −0.05 0.002 −0.12 −0.34 to 0.09 0.246
Medication history
Diuretic −0.13 −0.21 to −0.04 0.005 0.12 −0.63 to 0.88 0.747
β-Blocker 0.04 −0.03 to 0.11 0.282
ACEI −0.06 −0.13 to −0.02 0.156
CaAntagonist −0.01 −0.10 to 0.12 0.916
LVIDD 0 −0.01 to 0 0.333
NYHA 0.07 0.03 to 0.10 <0.00005 0.02 −0.04 to 0.09 0.501
eGFR −0.01 −0.01 to 0 <0.00005 −0.01 −0.01 to 0.0 <0.00005
prohormone and less tubular conversion into its active
form.
However, local production of prouroguanylin in
the kidney tubules with conversion into the active
uroguanylin hormone may also contribute to the total
uroguanylin-like activity in urine. It is unknown at
present the extent of the contribution of ﬁltered
prouroguanylin and tubular prouroguanylin to the
urinary uroguanylin bioactivity in HF, and whether
tubular production of the prohormone is up-regulated
in HF.
A further possibility is the increased synthesis of
proguanylin and prouroguanylin in patients with HF.
The site of increased synthesis is most probably the
intestine, as this has been shown to be the major
source of circulating prouroguanylin that undergoes
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post-secretory processing in the renal tubules [13,14].
The lack of a signiﬁcant correlation between plasma
prouroguanylin and proguanylin levels with LV dimen-
sions or LVEF suggests that their synthesis may not be
directly mediated by the pathophysiological processes
involved in HF. Dieplinger et al. [15] have reported
recently that both proguanylin and prouroguanylin
have limited diagnostic utility as biomarkers for acute
HF in patients presenting with acute dyspnoea, which
indicates that long- rather than short-term processes
may be responsible for elevations of their plasma
levels.
Up-regulation of guanylin and uroguanylin synthesis
has been observed in the renal [16] and intestinal
[17] tissues of rats fed a high-salt diet. Changes in
the intestinal mucosal microenvironment observed in
HF as a result of tissue hypoperfusion and mesenteric
ischaemia could potentially inﬂuence peptide synthesis
[18,19].
Forte [10] has hypothesized that prouroguanylin
secreted from the intestine in response to oral salt
loads acts as an endocrine hormone on the renal
tubule epithelial cells as part of an intestinal–renal
natriuretic axis. However, despite elevated plasma
proguanylin and prouroguanylin and increased urinary
bioactivity of uroguanylin, there remains a reduced
natriuretic response to an oral salt load in subjects
with HF compared with healthy subjects [1]. We
propose there may be renal hyporesponsiveness to
circulating plasma prouroguanylin, either from down-
regulation of uroguanylin receptor expression or altered
receptor function. The combined effect of impaired renal
response with reduced renal clearance of circulating
prouroguanylin would result in diminished natriuretic
and diuretic activity thus contributing to intravascular
volume expansion. This may explain the correlation
we observed with elevated plasma pro-peptide levels
and a history of hypertension. However, our ﬁnd-
ings are hypotheses-generating, and these possibilities
remain to be investigated in prospectively designed
studies.
Our present study had several limitations. This
was a small pilot study with a limited number of
healthy controls and patients with HF for comparison.
Plasma guanylin, uroguanylin or urine uroguanylin
were not measured since immunoassays speciﬁc for
these small molecules are difﬁcult to construct and
are not currently available. However, measurement of
these products may yield further information about
the processing of these natriuretic prohormones that
may be altered in HF in decompensated and treated
scenarios.
In conclusion, plasma levels of proguanylin and
prouroguanylin are increased in patients with HF,
particularly in symptomatic patients and those with
renal impairment. These novel hormonal systems may
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